ROMOSOZUMAB AS A NEW THERAPEUTIC OPTION IN POSTMENOPAUSAL OSTEOPOROSIS WITH VERY HIGH FRACTURE RISK: A CASE REPORT

Katarzyna Gołojuch; Patrycja Major; Przemysław Borowy; Jakub Smyk; Alicja Kamińska

doi:10.5114/hpc.2024.146121

eISSN: 2354-0265
ISSN: 2353-6942

Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO

Current issue Archive Online first About the journal Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

Send email

Copy url:

abstract:

Case report

ROMOSOZUMAB AS A NEW THERAPEUTIC OPTION IN POSTMENOPAUSAL OSTEOPOROSIS WITH VERY HIGH FRACTURE RISK: A CASE REPORT

Katarzyna Gołojuch

¹

,

Patrycja Major

²

,

Przemysław Borowy

^{3, 4}

,

Jakub Smyk

¹

,

Alicja Kamińska

⁵

Ludwik Rydygier Memorial Hospital, Kraków, Poland
5th Military Clinical Hospital in Kraków, Kraków, Poland
Department of Rheumatology and Immunology, J. Dietl Hospital, Krakow, Poland
Department of Rheumatology and Immunology, Andrzej Frycz-Modrzewski Kraków University, Kraków, Poland
Stefan Żeromski Specialist Hospital, Kraków, Poland

Health Prob Civil.

DOI: https://doi.org/10.5114/hpc.2024.146121

Online publish date: 2025/01/08

View full text Get citation

PlumX metrics:

Osteoporosis is a metabolic bone disease characterized by increased risk of fractures. Bisphosphonates and denosumab are widely used in the pharmacotherapy of osteoporosis. In severe cases, anabolic drugs and romosozumab (ROMO) – a monoclonal antibody that acts bi-modularly, blocking the sclerotin pathway, leading to bone formation and reduced bone resorption – are used. The paper presents data from one of the first post-trial ROMO therapies in Poland under real-data follow-up. The research paper presents a 61-year-old woman with severe postmenopausal osteoporosis and multiple osteoporotic fractures (MOF) of the thoracic and lumbar vertebrae after 5 times of vertebroplasty. The patient underwent a full differential diagnosis because of a suspected secondary cause of the disease, which was ruled out. Because of the patient's contraindication to bisphosphonates and very high fracture risk, denosumab was used in the treatment. Due to a decrease in bone mineral density (BMD) in the follow-up, dual-energy X-ray absorptiometry (DXA) and treatment with ROMO was started (Mar 2024). The treatment was well tolerated. No early adverse effects were observed. Due to its strong antifracture efficacy and the bi-modal mechanism of the latest guidelines for the diagnosis and management of osteoporosis in Poland, ROMO was recommend. This could be the first-line treatment in postmenopausal women at very high risk of fracture.

keywords:

ROMOSOZUMAB AS A NEW THERAPEUTIC OPTION IN POSTMENOPAUSAL OSTEOPOROSIS WITH VERY HIGH FRACTURE RISK: A CASE REPORT

Katarzyna Gołojuch 1 , Patrycja Major 2 , Przemysław Borowy 3, 4 , Jakub Smyk 1 , Alicja Kamińska 5

romosozumab, postmenopausal osteoporosis, DXA, fracture risk, BMD

Katarzyna Gołojuch

¹

,

Patrycja Major

²

,

Przemysław Borowy

^{3, 4}

,

Jakub Smyk

¹

,

Alicja Kamińska

⁵